Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya

Natalie R. Pritchett 1*, Stephen L. Burgert 2, Gwen A. Murphy 1, John D. Brockman 3, Russell E. White 2, Justus Lando 2, Robert Chepkwony 2, Mark D. Topazian 4, Christian C. Abnet 1, Sanford M. Dawsey 1 and Michael M. Mwachiro 2

Abstract

Background: Low serum selenium status has been associated with increased risk of esophageal squamous cell carcinoma (ESCC). East Africa is a region of high ESCC incidence and is known to have low soil selenium levels, but this association has not previously been evaluated. In this study we assessed the association of serum selenium concentration and the prevalence of esophageal squamous dysplasia (ESD), the precursor lesion of ESCC, in a cross-sectional study of subjects from Bomet, Kenya.

Methods: 294 asymptomatic adult residents of Bomet, Kenya completed questionnaires and underwent endoscopy with Lugol’s iodine staining and biopsy for detection of ESD. Serum selenium concentrations were measured by instrumental neutron activation analysis. Odds ratios (OR) and confidence intervals (95% CI) for associations between serum selenium and ESD were calculated using unconditional logistic regression.

Results: The mean serum selenium concentration was 85.5 (±28.3) μg/L. Forty-two ESD cases were identified (14% of those screened), including 5 (12%) in selenium quartile 1 (Q1), 5 (12%) in Q2, 15 (36%) in Q3, and 17 (40%) in Q4. Higher serum selenium was associated with prevalence of ESD (Q4 vs Q1: OR: 3.03; 95% CI: 1.05–8.74) and this association remained after adjusting for potential confounders (Q4 vs Q1: OR: 3.87; 95% CI: 1.06–14.19).

Conclusion: This is the first study to evaluate the association of serum selenium concentration and esophageal squamous dysplasia in an African population at high risk for ESCC. We found a positive association between higher serum selenium concentration and prevalence of ESD, an association contrary to our original hypothesis. Further work is needed to better understand the role of selenium in the etiology of ESCC in this region, and to develop effective ESCC prevention and control strategies.

Keywords: Esophageal, Squamous cell carcinoma, Squamous dysplasia, Selenium, Kenya

Background

Esophageal cancer is the sixth most common cause of cancer death in the world, but its occurrence varies greatly in different geographic regions [1]. Esophageal cancer has two epithelial subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma [2]. In many high income countries the incidence of ESCC has decreased, and is no longer the predominant form of esophageal cancer [3], but ESCC remains the dominant histologic type in several low and middle income countries where there are hot spot regions of high incidence [4–6].

East Africa is a region with high rates of esophageal cancer, a fact that has been known since the 1960s [7–9]. Data from the most recent Nairobi Cancer Registry found esophageal cancer to be one of the most common cancers among both men and women [10], and at Tenwek Hospital, in Bomet County in western Kenya, it is the most common cancer seen in both genders [11]. There is little published data on...
risk factors for ESCC in East Africa. Tobacco smoking and alcohol drinking account for 90% of ESCC in Western countries, but studies in other LMICs often report that these risk factors are much less important or absent [12, 13]. Low serum selenium has been reported to be an important risk factor for ESCC in the high risk regions of China [14, 15], but it has not been evaluated in Africa.

Selenium is an essential micronutrient in human nutrition that has been inversely associated with cancer risk in several previous studies, including one large prospective cohort study in China in which the low vs. high quartile attributable risk for ESCC incidence was 26% [14]. Similarly, low serum selenium levels were associated with an increased risk of developing ESCC and other cancers in large cohort studies in Finland and the Netherlands [16, 17]. Primary sources of dietary selenium include grains, leafy green vegetables, and animal products such as meat, fish, eggs, and dairy [18]. Soil selenium levels vary tenfold around the world, and the soil levels are reflected in locally grown plants and the serum of people who eat them [19]. Local soil selenium likely does not have much effect on populations such as those in the United States, where food supplies come from many different locations and are often transported long distances (an average of 1020 miles for final delivery of food) [20]. However, soil selenium can be important in areas where most dietary staples are locally produced and soil selenium levels are low [19].

The recommended Dietary Reference Intake for selenium from the Institute of Medicine is set at the amount needed to achieve a plateau in activity of the selenoprotein glutathione peroxidase [21]. Serum and plasma are the most useful tissues for assessing selenium status in humans, because selenium is stable in serum [22] and free of terrestrial contamination. In serum, full activity of the selenoprotein glutathione peroxidase is reached at a selenium concentration of 90 μg/L [23], so this value was used as the threshold to assess selenium sufficiency in this analysis [24]. There are, however, additional benefits from the provision of selenium beyond this saturation point. A serum selenium level of around 120 μg/L has been shown to ensure optimal SePP saturation, which is important for distribution of selenium around the body [25].

The east coast of Africa has a high proportion of selenium deficiency based on regional food composition table estimates [26]. In Kenya over 90% of individuals are estimated to be at risk for selenium deficiency because they do not meet the estimated average requirement for daily intake [26]. A recent ecologic study which reviewed micronutrient deficiencies in the high esophageal cancer incidence countries in eastern Africa found a significant association between esophageal cancer incidence and low selenium nutrient supply [18].

A number of intervention trials have attempted to test the cancer preventive effects of selenium supplementation for esophageal squamous cell carcinoma [27]. In China, the Linxian General Population Nutrition Intervention Trial tested the effect of 5.25 years of daily supplementation with a combination of selenium, vitamin E, and beta carotene, and this intervention conveyed a significant reduction in the risk of developing gastric cancer, but no apparent effect on ESCC risk [28]. A 10-year post-intervention follow-up study showed a strong age interaction such that younger people at trial baseline had a lower risk of ESCC if they received this combined agent [29]. An observational analysis of this same trial cohort reported an inverse association between baseline serum selenium concentration and the incidence of ESCC [14]. This study also documented that the population in this region of China has low selenium status, with a mean serum selenium of 72.2 μg/L, which is well below the 90 μg/L threshold for sufficiency used in this study. A second randomized, placebo-controlled trial, conducted within the same high ESCC risk region of China, evaluated the effect of selenomethionine supplementation on the natural history of esophageal squamous dysplasia (ESD). ESD is the precursor lesion of ESCC and the only histopathology that predicts the development of ESCC [30]. This ESD supplementation study in China found increased dysplasia regression and decreased dysplasia progression among participants with mild dysplasia at baseline [31].

Overall, these studies from China suggest that selenium may play an important chemoprotective role in ESCC carcinogenesis in populations with low selenium status and high rates of this disease, possibly due to the action of selenium as an antioxidant [19]. Western Kenya is a high incidence area for ESCC, and it is known to have low soil selenium levels. The association of serum selenium status and ESCC prevalence has not been evaluated previously in this population. We measured serum selenium concentrations among Kenyan adult volunteers who were participating in a prospective clinical study assessing the prevalence of ESD in asymptomatic residents of southwestern Kenya [32].

**Methods**

**Setting**

Tenwek Hospital is a 300 bed mission hospital which serves as the primary health care facility for about 600,000 people. The 50 km radius of the Tenwek Hospital catchment area consists of three traditionally recognized geographic zones, which are displayed in Fig. 1. The zones vary by climate, agriculture, animal husbandry, and economic activity, but not ethnicity:
Location A is characterized by fertile highlands with extensive tea and maize farms; Location B has dry sands with wheat farms and herds of cattle and goats; and Location C includes a mix of fertile and dry areas. Careful evaluation of differences in these three locations (in diet, soil selenium, etc.) have not yet been performed.

Participants
Asymptomatic adults were recruited during 2010–2013 from within the Tenwek catchment area, including villages in each of the traditional geographic zones. Details of the recruitment procedures have been previously described [32]. Inclusion criteria were: residence within 50 km of Tenwek Hospital, age 20–79 years, and a signed informed consent. In total, 333 subjects were enrolled in the study. There were 20 missed appointments due to scheduling conflicts, and 313 individuals that arrived at the clinic for the study procedure. Subjects were specifically questioned about symptoms of dysphagia, odynophagia, hematemesis, or recent weight loss, and persons with any of these symptoms were excluded. Other exclusion criteria included allergy to iodine or lidocaine and pre-existing medical conditions that would increase the risk of endoscopy. Seven subjects were excluded based on these criteria. Of the 306 participants in the parent endoscopic study, 294 (96%) had both esophageal biopsies, to enable histologic diagnosis of dysplasia, and serum samples collected.

Study approvals
Ethical approval for the parent endoscopic survey was obtained from the Institutional Review Boards of Tenwek Hospital and Kenyatta National Hospital in Nairobi, and all participants signed a written informed consent [32]. The selenium analysis was exempted from human subjects review by the National Institutes of Health Office of Human Subjects Research Protections (OHSRP).

Questionnaire data
Trained study interviewers conducted in-person interviews with all ESD study participants. The questionnaire included questions about demographics, home indoor air pollution, occupational history, farming methods, diet, cooking and food preservation methods, medical history, family history of cancer, tobacco use, alcohol consumption, signs and symptoms of upper gastrointestinal disease, oral health, perception of anthropometry, and reproductive history (for female participants only).
Blood samples
10 ml of venous blood was collected from all participants. Serum was separated, frozen at -20°C, and shipped to the analytic laboratory on dry ice.

Determination of serum selenium concentration
Serum selenium concentrations were measured by instrumental neutron activation analysis (INAA) at the University of Missouri Research Reactor. Samples were processed in three full run batches with the standard reference material National Institute of Standards and Technology (NIST) 909C. Three quality control (QC) samples were included in each batch along with one orphan run with a single QC sample. To generate the QC samples, serum from the 11 ESD study participants who did not have endoscopic biopsy results were pooled and then aliquoted into replicate daughter vials. 304 total samples were processed for this analysis, including the 10 QC samples. The measured Se value in 15 replicates of NIST 909C was 115 ± 9 μg/L and the certified value was 118.7 ± 3.3 μg/L. Among the QC replicates, the coefficient of variation for selenium was 10.5%. The limit of detection for the INAA method used in this study was 0.01 μg/g or 10 μg/L. The minimum selenium concentration measured in the study was 35 μg/L, and the 5th percentile was 47 μg/L.

Endoscopic procedures
Esophageal squamous dysplasia is the asymptomatic precursor lesion of ESCC, and a strong predictor of ESCC progression [33, 34]. ESD can be visualized endoscopically after mucosal iodine staining with Lugol’s iodine solution, and then targeted for biopsy [30]. Participants in this study underwent endoscopy with Lugol’s iodine staining of the esophagus and biopsy of unstained areas ≥5 mm in size for detection of ESD. The endoscopy was conducted under conscious sedation (intravenous diazepam or midazolam and fentanyl), with standard vital signs monitoring and post-endoscopy care, and endoscopic findings were recorded using standardized data forms. Formalin-fixed, paraffin embedded biopsies were stained with hematoxylin and eosin and were used for histologic diagnosis using previously described criteria [35]. The biopsies were read at the Department of Human Pathology, University of Nairobi and at the National Cancer Institute, and discrepancies were adjudicated by joint consultation.

Statistical analysis
Analyses were performed using STATA 13.0 software (StataCorp, College Station, Texas). Baseline characteristics were tabulated by serum selenium concentration. Significance of association was tested using a t-test for two-category and ANOVA for multiple-category variables. An alpha level of less than 0.05 was considered significant, and all tests were two sided.

Serum selenium concentrations were approximately normally distributed across the 294 study participants (Fig. 2). For inclusion in logistic regression models as a continuous variable, selenium concentrations were scaled to half of the interquartile range ((Q3-Q1)/2 = 20 μg/L). Serum selenium concentrations were also analyzed categorically in quartiles. Because this was a cross sectional study in which all participants were asymptomatic, selenium quartiles were calculated based on all individuals in the study population. We undertook univariate analysis of demographic variables to assess the associations with serum selenium status. Odds ratios (OR) and confidence intervals (95% CI) for associations between serum selenium and ESD were calculated using unconditional logistic regression, adjusting for potential confounders. P for trend values were assessed to determine the significance of the relationship between selenium and ESD in the quartile analysis.

Due to the lack of previous research, there were no assumptions about the relationship between selenium and ESD in the population of interest to include in the model a priori. Therefore, a crude model, an age- and sex-adjusted model, and a fully adjusted model were analyzed. The fully-adjusted model included the parameters in the previous analysis of the parent endoscopic screening study, which included adjustment for age (years), sex, education, residence location (A, B, or C), family history of cancer, family history of esophageal cancer, tobacco (regular use), and alcohol (regular use) [32]. Regular tobacco use was defined as at least once a day for at least six months, and regular alcohol use was defined as at least once a week for six months. As time of year may be an important factor for diet, month of
study recruitment was also included to adjust for any potential effects due to seasonality.

Adjustment for other social class variables (income, number of household members, water source), medical history (heartburn, regurgitation, difficulty swallowing), other exposure risks (cooking indoors, animal contact), and dietary variables (ugali, fruit and vegetable consumption) was considered. A stepwise exploration to include all variables with \( p < 0.10 \) did not significantly change the selenium OR calculations, so these additional variables were not included in the final model. Stratification by category for each dependent variable was also conducted with the fully adjusted model to assess if there was any change in association between selenium concentration and histologically confirmed ESD. While results were slightly different when stratified by location, the differences were not significant and each location still demonstrated a positive association between ESD and serum selenium status, so these results are not shown.

Results

294 participants had both biopsy and serum selenium results. There were nearly equal numbers of men (\( N = 158, 54\% \)) and women (\( N = 136, 46\% \)), as well as individuals age less than 50 years (\( N = 157, 53\% \)) and greater than or equal to 50 years (\( N = 137, 47\% \)). Of these, 174 study participants (59%) were below the 90 \( \mu \)g/L threshold used to assess selenium sufficiency in this study. Overall, the mean serum selenium concentration was 85.5 ± 28.3 \( \mu \)g/L, and the median serum selenium concentration was 79.4 \( \mu \)g/L (IQR: 63.9 \( \mu \)g/L–103.7 \( \mu \)g/L).

Forty-two ESD cases were identified (14% of those screened), including 5 cases (12%) in selenium quartile 1 (Se Q1), 5 (12%) in Se Q2, 15 (36%) in Se Q3, and 17 (40%) in Se Q4.

Table 1 presents the distributions of patients, mean serum selenium concentrations, and significance of association with selenium for all ESD study participants across baseline characteristics. Serum selenium was found to be strongly associated with location of residence (\( p < 0.001 \)). The mean selenium concentrations in location A (70.6 ± 19.6 \( \mu \)g/L) and location C (81.5 ± 22.9 \( \mu \)g/L) were significantly lower than the mean concentration in location B (118.8 ± 25.8 \( \mu \)g/L). The occurrence of ESD was also significantly associated with selenium concentration (\( p = 0.02 \)). Participants diagnosed with dysplasia had a higher mean serum selenium concentration (94.9 ± 29.0 \( \mu \)g/L) than participants who were diagnosed as normal or esophagitis (83.9 ± 28.0 \( \mu \)g/L).

The associations of continuous or categorical measures of serum selenium and ESD using unconditional logistic regression are shown in Table 2. Results are shown for the crude model, the age- and sex-adjusted model, and a model further adjusted for six other potentially confounding variables. In the continuous analysis, scaled to half of the interquartile range (20 \( \mu \)g/L), every unit increase in serum selenium concentration was significantly associated with ESD in all three models (fully adjusted model OR: 1.42; 95% CI: 1.04–1.93). In the quartile analysis, the association of selenium concentration and ESD increased from the lowest to the highest quartile of serum selenium in all models (\( p \) for trend ≤0.02), but only in the highest quartile of serum selenium was the association statistically significant (fully adjusted model OR: 3.87; 95% CI: 1.06–14.19).
Discussion

We found a significant positive association between higher serum selenium concentration and prevalence of ESD, the precursor lesion of ESCC, which was contrary to our original hypothesis. Previous studies have found a significant inverse relationship between serum selenium concentration and ESCC risk [14], so this unexpected result should be interpreted with caution [36]. The relationship between serum selenium concentration and ESD may truly be different from the relationship between selenium and ESCC, but this seems unlikely. It is also unlikely that this result was due to reverse causation, since all participants were asymptomatic, so their disease probably did not affect their eating habits. We think it is more likely that the unexpected findings of this cross-sectional study may be the result of length biased sampling [37]. If selenium is protective against ESCC carcinogenesis, as prior literature suggests, then it is possible that subjects with higher selenium status may have slower progression of ESD, which would make subjects with ESD more likely to be sampled in a cross-sectional screening study. In this case, prospective studies may still show an inverse relationship between serum selenium concentration and odds of developing ESD.

Selenium is an essential element that is necessary in small amounts for human health [38], but at a high dose selenium becomes toxic and may even promote carcinogenesis [39]. In the United States Nutritional Prevention of Cancer trial there was no protective effect of selenium supplementation among participants whose baseline plasma selenium concentrations were in the upper tertile of baseline plasma selenium (>121.6 μg/L) [40]. The protective effect was most prominent in those in the lowest tertile at baseline (≤105.2 μg/L). More research is needed to better understand how selenium may act differently in individuals with different nutritional status [38]. However, it seems clear that the population observed in this study is on the low end of the selenium distribution.

This study is noteworthy because it provides documentation that serum selenium status in this population is low. The threshold used to assess selenium sufficiency in serum in this analysis was 90 μg/L [24]. The majority (59%) of participants in this study fell below this threshold. The mean serum selenium concentration was 85.5 μg/L, which was higher than the 72.2 μg/L mean concentration found in the high risk population of Linxian, China [14], but was significantly lower than the 136.7 μg/L mean concentration found in the third National Health and Nutrition Examination Study (NHANES) in the United States [41]. Fewer than 6% of individuals in the ESD study population had serum selenium concentrations higher than the NHANES mean value.

Maize grain is likely the primary determinant of selenium intake in this region [42]. Many residents grow their own maize in small plots around their homes, and use this locally grown maize to make their own ugali (the dietary staple in this population). Thus, differences in soil selenium in the area could be reflected in serum selenium status. Unfortunately, our study did not collect the data needed to evaluate these possibilities, and neither the soil selenium nor the selenium content of ugali have been measured in this area. In our analysis, there was no correlation found between ugali intake and serum selenium. Increased ugali consumption may be an indicator of lower socioeconomic status, in which case the most important effect of eating more ugali may be not eating a more varied healthy diet (which could also

| Table 2 Odds Ratios, 95% CI, and p values for the association between serum selenium and prevalent ESD in the Tenwek ESD study |
|---------------------------------------------------------------|
| Scaled Serum Selenium<sup>a</sup> | OR  | 95% CI       | p value |
|----------------------------------|-----|--------------|---------|
| Crude Model                      | 1.29| 1.04–1.61    | 0.02    |
| Age and Sex Adjusted             | 1.30| 1.04–1.63    | 0.02    |
| Fully Adjusted<sup>b</sup>       | 1.42| 1.04–1.93    | 0.03    |
| Selenium Quartile               |     |              |         |
| Q1                               |     |              |         |
| Q2                               |     |              |         |
| Q3                               |     |              |         |
| Q4                               |     |              |         |
| Mean Concentration (μg/L)        |     |              |         |
| Q1                               | 53  | 68           | 87      | 122     |
| Q2                               | 36-61| 62-73       | 74-99   | 100-188 |
| Q3                               |     |              |         |
| ESD Cases, N (%)                 |     |              |         |
| Ref                              |     |              |         |
| Crude Model                      | 1   | 1.02         | 2.42    | 0.83–7.04 | 3.03 | 1.05–8.74 | 0.01 |
| Age and Sex Adjusted             | 1   | 1.02         | 2.25    | 0.76–6.66 | 2.95 | 1.02–8.55 | 0.02 |
| Fully Adjusted<sup>b</sup>       | 1   | 1.13         | 2.71    | 0.84–8.69 | 3.87 | 1.06–14.19| 0.02 |

<sup>a</sup>Selenium scaled to ½ interquartile range (20 μg/L)

<sup>b</sup>Adjusted for age (years), sex, education, location (A, B, or C), family history of cancer, family history of esophageal cancer, tobacco (regular use), and alcohol (regular use)
include other selenium sources), rather than being a direct predictor of serum selenium status.

Our study has a number of notable strengths. It is the first study to look specifically at the relationship between serum selenium and the presence of ESD in a population in a high ESCC incidence region in Africa. All patients in this prospective, population-based study were interviewed directly, which allowed for complete data collection. Our study used the best available method (Lugol’s chromoendoscopy, biopsy of unstained areas, and histologic diagnosis) to identify ESD status, and we directly measured serum selenium concentration in blood samples, in contrast to estimating individual selenium availability from dietary data. However, our study was limited by its relatively small size, with only 42 cases of dysplasia (33 mild, eight moderate, and one severe), and the fact that we measured selenium concentrations at only one time point, which might not be broadly representative of general selenium status.

Conclusion
This is the first study to evaluate the association of serum selenium concentration and esophageal squamous dysplasia in an African population at high risk for ESCC. We found a significant positive association between serum selenium concentration and ESD, an association contrary to our original hypothesis. More work needs to be done to understand the role of selenium and other risk factors in the etiology of ESCC in this region, and to develop effective preventative and control measures.

Abbreviations
CI: Confidence interval; ESCC: Esophageal squamous cell carcinoma; ESD: Esophageal squamous dysplasia; INAA: Instrumental neutron activation analysis; IQR: Interquartile range; LMIC: Low and middle income country; NCI: National cancer institute; NHANES: National health and nutrition; examination study; NIH: National institute of health; NIST: National institute of standards and technology; OHSRP: Office of human subjects research protections; OR: Odds ratio; Q: Quartile; QC: Quality control; SD: Standard deviation

Acknowledgements
The authors would like to thank the patients and clinicians at Tenwek hospital that make this work possible.

Funding
This research was made possible by the African Organization for Research and Training in Cancer (AORTC), in collaboration with the U.S. National Institutes of Health’s (NIH) National Cancer Institute (NCI) Office of International Affairs. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
All data generated during this study are included in this published article. The data and questionnaire analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MM, SB, RW, MT, SD, and CA conceptualized and designed this study; MM, JL, RC, and SB performed clinical procedures; JB conducted the laboratory analysis; NP, GM, CA, SD, and MW analyzed and interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical approval for the parent endoscopic survey was obtained from the Institutional Review Boards of Tenwek Hospital and Kenyatta National Hospital in Nairobi, and all participants signed a written informed consent. The selenium analysis was exempted from human subjects review by the National Institutes of Health Office of Human Subjects Research Protections (OHSRP).

Consent for publication
Not applicable.

Competing interests
The authors prepared this report in their roles as employees of their respective institutions. They have no financial or other potential conflict of interest with regard to this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1National Cancer Institute, Bethesda, MD, USA. 2Tenwek Hospital, Bomet, Kenya. 3University of Missouri Research Reactor Center, Columbia, MO, USA. 4Mayo Clinic, Rochester, Minnesota, USA.

Received: 21 December 2016 Accepted: 23 November 2017 Published online: 08 December 2017

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2013;136: E359–86. doi:10.1002/ijc.29210.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52. doi:10.1056/NEJMoa030510.
3. Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer—an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230–44. doi:10.1038/nrgastro.2012.236.
4. Cheng ML, Zhang L, Boris M, Chukunenga E, Dzamamala C, Koor A, Wabinga HR, Hatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol. 2015;39:143–9. doi:10.1016/j.canep.2015.01.001. PMC4470609.
5. Gabel J, Chamberlain RW, Ngoma T, Mwaiselage J, Schmid KK, Kahesa C, Soliman AS. Clinical and epidemiologic variations of esophageal cancer in Tanzania. World J Gastrointest Oncol. 2016;8:314–20. doi:10.4251/wjgo.v8.i3. 314. PMC479617.
6. Kayamba V, Sinkala E, Mwanamakondo S, Sokolo R, Kawimbe B, Amadi B, Zulu I, Nzaisenga JB, Banda T, Mumbye C, et al. Trends in upper gastrointestinal diagnosis over four decades in Lusaka, Zambia: a retrospective analysis of endoscopic findings. BMC Gastroenterol. 2015;15:127. doi:10.1186/s12876-015-0353-b. 4596361.
7. Ahmed N, Cook P. The incidence of the cancer of the oesophagus in West Kenya. Br J Cancer. 1969;23:302–7. 12200828.
8. McCormack VA, Menya D, Munishi MO, Dzamalala C, Gasmelseed N, Leon Roux M, Assefa M, Osano O, Watts M, Mwasamwaja AO, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting-specific exposures to known and putative risk factors. Int J Cancer. 2017;140:259–71. doi:10.1002/ijc.30292.
9. Butkitt DP. Distribution of cancer in Africa. Proc R Soc Med. 1973;66:312–4. PMC1644993
10. Korir A, Okerosi N, Ronoh V, Mutuma G, Parkin M. Incidence of cancer in Nairobi, Kenya (2004–2008). Int J Cancer. 2015;137:2053–6. doi:10.1002/ijc.29210.
11. Parker RK, Davsey SM, Abnet CC, White RE. Frequent occurrence of esophageal cancer in young people in western Kenya. Dis Esophagus. 2010;23:128–35. doi:10.1111/j.1445-205X.2009.00977.x. PMC3050315.
12. Castellsague X, Munoz N, De Stefani E, Victoria CG, Castelleto R, Rolon PA, Quintana MJ. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer. 1999;82:657–64.
13. Nasrollahzadeh D, Kamangar F, Aghchelki S, Sotoudeh M, Islami F, Abnet CC, Shakeri R, Poursamans A, Marjani HA, Nourie M, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98:1857–63. doi:10.1038/sj.bjc.6604369 PMC2410115.

14. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, Fraumeni JF Jr, Blot WJ, Dong ZW, Taylor PR. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000;92:1753–63.

15. Wei WQ, Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Sun XD, Fan JH, Gunter EW, Taylor PR, Mark SD. Prospective study of serum selenium concentrations and esophageal and gastric cancer, heart disease, stroke, and total death. Am J Clin Nutr. 2004;79:890–5.

16. Knekt P, Aromaa A, Maetela J, Ahlfang H, Aaran RK, Hakama M, Hakulinen T, Peto R, Teppo L. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst. 1990;82:864–8.

17. Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 2010;138:1704–13. doi:10.1053/j.gastro.2009.12.004.

18. Rayman MP. Selenium and human health. Lancet. 2012;379:1256–68. doi:10.1016/S0140-6736(11)61452-9.

19. Boosalis MG. The role of selenium in chronic disease. Nutr Clin Pract. 2008;23:152–60. doi:10.1177/088453360836314532.

20. Weber CL, Matthews HS. Food-miles and the relative impacts of food choices in the United States: Environ Sci Technol. 2008;42:3508–13.

21. Monsen ER. Dietary intake references for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids (vol 100, pg 638, 2000). J Am Diet Assoc. 2000;100:1008–9.

22. Combs GF Jr. Biomarkers of selenium status. Nutrients. 2015;7:2209–42. doi:10.3390/nu7042209 PMC4425141.

23. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr. 2004;58:391–402. doi:10.1038/sj.ejcn.1601800.

24. Duffield AJ, Thomson CD, Hill KE, Williams S. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr. 1999;70:896–903.

25. Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, Wang L, Byrne DW, Bux RF. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr. 2010;92:525–31. doi:10.3945/ajcn.2010.296421 PMC2921536.

26. Joy EJ, Ander EL, Young SD, Black CR, Watts MJ, Chilimba AD, Silins CB, Syame EW, Kalimbi AA, Hurst R, et al. Dietary mineral supplies in Africa. Physiol Plant. 2014;151:208–21. doi:10.1111/ppl.12144 4235459.

27. Combs GF Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr. 2005;135:343–7.

28. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gall M, Li GY, et al. Nutrition intervention trials in Linxian, China: supplementation with vitamins and minerals: follow-up of the Linxian general population nutrition intervention trial. J Natl Cancer Inst. 1993;85:1483–92.

29. Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, Johnson LL, Gall MH, Dong ZW, Yu B, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian general population nutrition intervention trial. J Natl Cancer Inst. 2009;101:507–18. doi:10.1093/jnci/djp037 2664089.

30. Taylor PR, Abnet CC, Dawsey SM. Squamous dysplasia–the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2013;22:540–52. doi:10.1158/1055-9965.EPI-12-1347 PMC3681095.

31. Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005;129:863–73. doi:10.1053/j.gastro.2005.06.024.

32. Mwachiro MM, Burgtst SL, Landon J, Chepseny R, Bett C, Josie C, Abnet CC, Githanga J, Waweru W, Giffen CA, et al. Esophageal Squamous dysplasia is common in asymptomatic Kenyans: a prospective, community-based, cross-sectional study. Am J Gastroenterol. 2016;111:26. doi:10.1038/ajg.2016.26.

33. Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, Li JY, Blot WJ, Li B, Taylor PR. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer. 1994;74:1686–82.